[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$akesf](/topic/$akesf)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$SMMT $AKESF Summits dual-acting drug scores lung cancer win via @BioPharmaDive"  
[X Link](https://x.com/MarcJacksonLA/status/1980649470560989556) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-21T14:56Z 7586 followers, XXX engagements


"Great Data out on $SMMT Huge move coming Monday This can see a $XXXXX move"  
[X Link](https://x.com/trentkelp/status/1979969463895146528) [@trentkelp](/creator/x/trentkelp) 2025-10-19T17:54Z 7591 followers, 1643 engagements


"$AKESF $SMMT $ONC $MRK ESMO 2025: Akeso Summit's ivonescimab beats PD-1 in first chemo combo win in first-line NSCLC - Ivonescimab and chemo reduced the risk of progression or death by XX% compared with BeOnes Tevimbra and chemo in first-line squamous NSCLC"  
[X Link](https://x.com/MarcJacksonLA/status/1979943276066279807) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-19T16:10Z 7590 followers, XXX engagements


"$SMMT $AKESF ESMO 2025: Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by XX% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase X Clinical Trial in 1L NSCLC: Median PFS of XXXXX Months vs. XXXX Months Respectively for Patients Receiving Ivonescimab Plus Chemotherapy vs."  
[X Link](https://x.com/MarcJacksonLA/status/1979930068978991176) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-19T15:18Z 7590 followers, 2104 engagements